Glutamate Carboxypeptidase II
"Glutamate Carboxypeptidase II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A metallocarboxypeptidase that is predominantly expressed as a membrane-bound enzyme. It catalyzes the hydrolysis of an unsubstituted, C-terminal glutamyl residue, typically from PTEROYLPOLYGLUTAMIC ACIDS. It was formerly classified as EC 3.4.19.8.
| Descriptor ID |
D043425
|
| MeSH Number(s) |
D08.811.277.656.350.245.400 D08.811.277.656.350.555.500 D08.811.277.656.675.555.500
|
| Concept/Terms |
Glutamate Carboxypeptidase II- Glutamate Carboxypeptidase II
- Carboxypeptidase II, Glutamate
- FOLH1 Protein
- N-Acetylaspartylglutamate Peptidase
- N Acetylaspartylglutamate Peptidase
- Peptidase, N-Acetylaspartylglutamate
- NAALADase L
- NAAG Peptidase
- NAALADase
- NAALADase II
- Folate Hydrolase I
- Hydrolase I, Folate
- N-Acetylated-alpha-Linked Acidic Dipeptidase
- Acidic Dipeptidase, N-Acetylated-alpha-Linked
- Dipeptidase, N-Acetylated-alpha-Linked Acidic
- N Acetylated alpha Linked Acidic Dipeptidase
|
Below are MeSH descriptors whose meaning is more general than "Glutamate Carboxypeptidase II".
Below are MeSH descriptors whose meaning is more specific than "Glutamate Carboxypeptidase II".
This graph shows the total number of publications written about "Glutamate Carboxypeptidase II" by people in this website by year, and whether "Glutamate Carboxypeptidase II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 3 | 0 | 3 |
| 2007 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glutamate Carboxypeptidase II" by people in Profiles.
-
True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study. J Nucl Med. 2024 Jul 01; 65(7):1080-1086.
-
Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives. Cancer Biother Radiopharm. 2021 Apr; 36(3):237-251.
-
Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. Technol Cancer Res Treat. 2017 12; 16(6):1194-1201.
-
What's in a Label? Radioimmunotherapy for metastatic prostate cancer. Clin Cancer Res. 2013 Sep 15; 19(18):4908-10.
-
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med. 2012 Jun 27; 4(140):140ra86.
-
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther. 2011 Oct; 21(5):299-314.
-
Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 2007 Nov 01; 67(21):10528-37.
-
Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 2005 Oct 01; 65(19):9080-8.
-
Molecular imaging in prostate cancer. J Cell Biochem. 2003 Oct 15; 90(3):473-83.
-
Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res. 2003 Aug 15; 9(9):3260-71.